Updated NETs Clinical Trials

• A Clinical Risk Score to Stratify High-risk PanNETs

  Conditions: Pancreatic Neuroendocrine Tumors Interventions: Procedure: Curative surgical resection Sponsors: Fudan University; West China Hospital; IRCCS San Raffaele Completed

• Cannabidiol Oil for Treatment-Resistant Major Depression

  Conditions: Major Depressive Disorder (MDD); Treatment-resistant Depression (TRD) Interventions: Drug: Full-spectrum CBD oil 100 mg/mL; Drug: Placebo oil (MCT oil) Sponsors: Universidade do Sul de Santa Catarina; Federal University of Latin American Integration; Associação Cannabis Sem Fronteiras - ACSF Recruiting

• Temozolomide in Aggressive Pituitary Neuroendocrine Tumors: A Latin American Multicenter Retrospective Cohort (TMZ-LATAM)

  Conditions: Pituitary Neoplasms Interventions: Drug: temozolamide; Drug: Temozolamide Sponsors: University of Sao Paulo General Hospital Not yet recruiting

• Prevalence of Chapman Reflex Points in Medical Students and Their Association With Visceral Symptoms

  Conditions: Healthy; Autonomic Nervous System Diseases; Lymphatic Diseases; Somatic Dysfunction; Chapman Reflex Points Interventions: Procedure: Chapman Reflex Point Examination Sponsors: The Touro College and University System Completed

• Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms

  Conditions: Neuroendocrine Neoplasm; Neuroendocrine Carcinomas; Neuroendocrine Tumors Interventions: Drug: CTX-471 Sponsors: Compass Therapeutics Not yet recruiting

• An Experimental Study of Belzutifan Impact on Catecholamine Metabolism

  Conditions: Pheochromocytoma and Paraganglioma (PPGL); Pheochromocytoma Malignant; Pheochromocytoma, Metastatic; Pheochromocytoma/Paraganglioma; Pheochromocytoma Interventions: Drug: Belzutifan Sponsors: Cambridge University Hospitals NHS Foundation Trust; University of Cambridge Recruiting

• IL-6 and Cortisol Responses to Cycling Exercise

  Conditions: Exercise Physiology; Cardiorespiratory Fitness; Interleukin-6; Cortisol Interventions: Behavioral: Wingate Anaerobic Cycling Test; Behavioral: YMCA Submaximal Cycling Test Sponsors: Ondokuz Mayıs University Completed

• Autonomic and Peripheral Neurochemical Responses to Maximal Rowing Exercise

  Conditions: Healhty Interventions: Other: Maximal 6,000-m rowing ergometer test Sponsors: Poznan University of Physical Education; Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz Completed

• 211At-MABG in Adults With Advanced Neuroendocrine Cancers

  Conditions: Pheochromocytoma; Paraganglioma; Neuroendocrine Tumors; Medullary Thyroid Cancer; Bronchial Carcinoid; Gastroenteropancreatic Neuroendocrine Neoplasm Interventions: Drug: 1 MBq/k of 211At-MABG Fractionated; Drug: 2 MBq/k1 of 211At-MABG Fractionated; Drug: 4 MBq/k of 211At-MABG Fractionated Sponsors: University of Pennsylvania; National Institutes of Health (NIH); National Cancer Institute (NCI) Not yet recruiting

• Adjunctive Resonance-Based Chinese Five-Element Music Intervention for Depressive Disorders and Anxiety Symptoms in Male Inpatients

  Conditions: Depressive Disorder; Anxiety; Randomised Controlled Trial Interventions: Other: Resonance-Based Chinese Five-Element Music Intervention(RFEMI) plus pharmacotherapy group; Other: Resonance-Based Chinese Five-Element Music Intervention(RFEMI) plus pharmacotherapy group Sponsors: University of Malaya Enrolling by invitation

• A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany

  Conditions: Gastro-enteropancreatic Neuroendocrine Tumor Sponsors: Novartis Pharmaceuticals Completed

• Effects of a 12-week Supervised Exercise Program Post Bariatric Surgery on Body Composition, Muscle Strength, and Insulin Resistance

  Conditions: Bariatric Surgery; Exercise; Body Composition Changes Interventions: Other: 12-week supervised exercise program Sponsors: Laval University Completed

• Study of SNH-118110 in Advanced Solid Tumors

  Conditions: Solid Tumors Interventions: Drug: SNH-118110 Soft Capsules Sponsors: ScinnoHub Pharmaceutical Co., Ltd. Not yet recruiting

• AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)

  Conditions: Neuroendocrine (NE) Tumors; Advanced NET of GI Origin Interventions: Drug: AUR103 Calcium Sponsors: Aurigene Discovery Technologies Limited Not yet recruiting

• Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy

  Conditions: Prostate Cancer; Neuroendocrine Prostate Cancer (NEPC) Interventions: Drug: Sacituzumab Tirumotecan Sponsors: Virginia Commonwealth University; Merck Sharp & Dohme LLC Not yet recruiting

• A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

  Conditions: Gastroenteropancreatic Neuroendocrine Tumor Sponsors: Novartis Pharmaceuticals Recruiting

• Effect of NAE on Polycystic Ovarian Syndrome (PCOS)

  Conditions: Polycystic Ovarian Syndrome (PCOS); Infertility; Metabolic Disorders Interventions: Drug: Herbal Formulation; Drug: Metformin XR; Drug: Metformin 750 mg and herbal formulation 500 mg Sponsors: Jinnah Sindh Medical University Completed

• Clinically Actionable Tumor-Associated Antigens in Prostate Cancer

  Conditions: Prostate Cancer; Metastatic Prostate Cancer; Metastatic Prostate Cancer (mCRPC) Interventions: Other: Immunohistochemistry (IHC) Staining and Analysis Sponsors: Peking University First Hospital Active, not recruiting

• DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  Conditions: Extrapulmonary Neuroendocrine Cancer Interventions: Drug: Obrixtamig; Drug: Carboplatin; Drug: Etoposide; Device: Ventana DLL3 RxDx assay Sponsors: Boehringer Ingelheim Not yet recruiting

• Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

  Conditions: Solid Tumor; Small Cell Lung Cancer (SCLC); High Grade Neuroendocrine Cancer; Small Cell Carcinomas of Non-lung Origin; Non-small Cell Lung Cancer (NSCLC); Prostate Cancer; Ovarian Cancer; Renal Carcinoma (Clear and Non-clear Cell); Head and Neck Squamous Cell Carcinoma (HNSCC); Hepatic Cancer; Gastric Cancer; Triple-negative Breast Cancer (TNBC) Interventions: Drug: EXS74539 Sponsors: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. Recruiting

• Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

  Conditions: Extensive-Stage Small Cell Lung Cancer; Extrapulmonary Neuroendocrine Carcinoma; Recurrent or Refractory; Solid Tumors Interventions: Drug: Autologous B7-H3 CAR T; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: National Cancer Institute (NCI) Not yet recruiting

• Remotely-Delivered Cognitive Behavioral Stress Management for Breast Cancer (R-CBSM)

  Conditions: Breast Cancer Interventions: Behavioral: Remotely Delivered Cognitive Behavioral Stress Management Intervention (R-CBSM); Behavioral: Standard of Care Survivorship Care Planning Sponsors: University of Miami; National Cancer Institute (NCI) Recruiting

• Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

  Conditions: Meningioma; Glioblastoma; Acoustic Neuroma; Brain Cancer; Pituitary Adenoma Interventions: Drug: Panitumumab-IRDye800 Sponsors: Eben Rosenthal Recruiting

• A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

  Conditions: Small Cell Lung Cancer (SCLC ); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); Gastroenteropancreatic NEC (GEP NEC); Neuroendocrine Prostate Cancer (NEPC) Interventions: Biological: ML261 Sponsors: Moonlight Bio, Inc Not yet recruiting

• ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

  Conditions: Merkel Cell Carcinoma; Merkel Cell Carcinoma, Stage III; Merkel Cell Carcinoma, Stage IV Interventions: Drug: ASTX727 + retifanlimab Sponsors: University of Wisconsin, Madison Not yet recruiting

• Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis

  Conditions: NF2-related Schwannomatosis Interventions: Device: Auto-captioning Glasses Sponsors: Massachusetts General Hospital Active, not recruiting

• A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC

  Conditions: SCLC; NEC Interventions: Drug: HLX3901 Sponsors: Shanghai Henlius Biotech Recruiting

• Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

  Conditions: Merkel Cell Carcinoma, Stage I; Merkel Cell Carcinoma, Stage II; Neoadjuvant Immunotherapy Interventions: Drug: Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles; Drug: Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Prof. Gutzmer, Skin Cancer Center Minden, Johannes-Wesling-Klinikum Minden, Germany; Universität Duisburg-Essen; Regeneron Pharmaceuticals Recruiting

• TheraSphere Japan Pre-Market Study

  Conditions: Liver Neoplasms Interventions: Device: TheraSphere Y-90 glass microsphere Sponsors: Boston Scientific Corporation Recruiting

• Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients

  Conditions: SCLC, Extensive Stage; Neuroendocrine Tumors Interventions: Biological: Biological/Vaccine: NK Cell Therapy Product Derived from Induced Pluripotent Stem Cells (iPSCs) Engineered with Anti-DLL3 CAR Construct, Followed by Differentiation and Expansion Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Neukio Biotherapeutics (Shanghai) Co., Ltd. Recruiting

• Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

  Conditions: Neuroendocrine Tumors Sponsors: Ipsen Recruiting

• Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

  Conditions: Advanced Pheochromocytoma and Paraganglioma; PCPG Interventions: Drug: ONC206; Drug: ONC206: Dose 1; Drug: ONC206: Dose 2 Sponsors: Jazz Pharmaceuticals Recruiting

• Measuring Vestibular Organ Function With Weak Alternating Current Stimulation

  Conditions: Vestibular Disorder; Vestibular Schwannoma; Vestibular Neuritis Interventions: Device: Active transcranial electrical vestibular stimulation (Active EVS); Device: Sham transcranial electrical vestibular stimulation (Sham EVS); Device: Control measurement Sponsors: Aalto University; Helsinki University Central Hospital; Business Finland Enrolling by invitation

• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

  Conditions: Small-cell Lung Cancer; Neuroendocrine Carcinomas; Solid Tumor Show to Express DLL3 Interventions: Drug: IDE849; Drug: durvalumab; Drug: IDE161; Drug: Carboplatin Sponsors: IDEAYA Biosciences Recruiting

• SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors

  Conditions: Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma); Cancer Survivors; Cancer Survivorship Interventions: Behavioral: Oncology-informed yoga; Behavioral: SMART Sponsors: Barbara Nemesure Recruiting

• Esketamine Combined With Magnesium Sulfate for Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy

  Conditions: Laparoscopic Cholecystectomy; Alleviate Postoperative Fatigue Syndrome Interventions: Drug: Esketamine; Drug: Magnesium sulfate; Drug: Esketamine and Magnesium sulfate; Drug: Saline Sponsors: The Second People's Hospital of Huai'an Completed

• A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

  Conditions: SST2-positive Neuroendocrine Neoplasms; Neuroendocrine Tumors; Neuroendocrine Neoplasm Interventions: Drug: CRN09682 Sponsors: Crinetics Pharmaceuticals Inc. Recruiting

• Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

  Conditions: Anal Carcinoma; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Cholangiocarcinoma; Colorectal Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Head and Neck Carcinoma; Hematopoietic and Lymphatic System Neoplasm; Hepatocellular Carcinoma; Lung Carcinoma; Malignant Adrenal Gland Neoplasm; Malignant Brain Neoplasm; Malignant Neoplasm of Unknown Primary; Malignant Solid Neoplasm; Malignant Testicular Neoplasm; Malignant Uterine Neoplasm; Neuroendocrine Neoplasm; Ovarian Carcinoma; Pancreatic Carcinoma; Penile Carcinoma; Pleural Carcinomatosis; Primary Peritoneal Carcinoma; Prostate Carcinoma; Salivary Gland Carcinoma; Sarcoma; Skin Carcinoma; Solitary Fibrous Tumor; Thymus Carcinoma; Thyroid Gland Carcinoma; Thyroid Gland Medullary Carcinoma; Urothelial Carcinoma; Vaginal Carcinoma Interventions: Procedure: Computed Tomography; Other: Fludeoxyglucose F-18; Radiation: Gallium Ga 68 FAPi-46; Procedure: Positron Emission Tomography Sponsors: Jonsson Comprehensive Cancer Center Active, not recruiting

• Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease

  Conditions: Cushing Disease Interventions: Diagnostic Test: [18F]FET PET-MRI Sponsors: University Hospital, Basel, Switzerland; Erasmus Medical Center Enrolling by invitation

• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

  Conditions: Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor Interventions: Drug: Paltusotine; Drug: Placebo Sponsors: Crinetics Pharmaceuticals Inc. Recruiting

• CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

  Conditions: Medulloblastoma Sponsors: St. Jude Children's Research Hospital Recruiting

• Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  Conditions: Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET) Interventions: Drug: Zanzalintinib; Drug: Everolimus Sponsors: Exelixis Recruiting

• Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole

  Conditions: Major Depressive Disorder (MDD); Rumination Interventions: Drug: Escitalopram; Drug: Aripiprazole 5mg Sponsors: Central South University; Second Xiangya Hospital of Central South University; National Natural Science Foundation of China Active, not recruiting

• Affect-based Impulsivity in Borderline Personality Disorder

  Conditions: Borderline Personality Disorder (BPD); Healthy Controls Group - Age and Sex-matched Interventions: Behavioral: Stress Induction Sponsors: University of North Carolina, Chapel Hill; North Carolina Translational and Clinical Sciences Institute Recruiting

• IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

  Conditions: Peritoneal Mesothelioma; Gestational Trophoblastic Tumor; Anaplastic Thyroid Carcinomas; Gastroenteropancreatic Neuroendocrine Tumor; Carcinoid Tumor; Thymic Carcinoma Interventions: Drug: DOMVANALIMAB + ZIMBERELIMAB; Drug: DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 Sponsors: Hospices Civils de Lyon Active, not recruiting

• Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases

  Conditions: Malignant Brain Neoplasm; Malignant Solid Neoplasm; Multiple Sclerosis; Neuroendocrine Tumor; Prostate Carcinoma Interventions: Procedure: Biospecimen Collection; Other: Exercise Intervention; Procedure: Magnetic Resonance Imaging; Other: Questionnaire Administration; Procedure: Respiratory Therapy Sponsors: Mayo Clinic Recruiting

• Window On the Brain

  Conditions: Disorders of Consciousness Interventions: Device: Ultrasound technique for diagnosis; Focused Ultrasound Stimulation for intervention Sponsors: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; IRCCS Istituto delle Scienze Neurologiche di Bologna; S.Anna Rehabilitation Institute; IRCCS Centro Neurolesi Bonino Pulejo Completed

• Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

  Conditions: Extensive Stage Small Cell Lung Cancer Interventions: Drug: Tarlatamab Sponsors: Amgen Active, not recruiting

• [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

  Conditions: Sinonasal Neuroendocrine Carcinoma; Nasopharyngeal Carcinoma; Esthesioneuroblastoma; Olfactory Neuroblastoma; Somatostatin Receptor Positive; Small Cell Lung Cancers; Pheochromocytoma/Paragangliomas; Kidney Cancers; Head and Neck Tumors; Gastrointestinal Neuroendocrine Tumors Interventions: Drug: 68Ga-DOTATATE; Drug: [203Pb]VMT-alpha-NET; Drug: [212Pb]VMT-alpha-NET Sponsors: National Cancer Institute (NCI) Recruiting

• Heart Analysis in GATED-PET in Patients Having a Gallium-68-DOTATOC PET/CT Exam for Oncology Indication

  Conditions: Cardiac Inflammation Interventions: Other: Cardiac ECG-gated PET imaging will added Sponsors: Central Hospital, Nancy, France Recruiting